Hiroshi Kiyama

Hiroshi Kiyama

Auto-generated profile, based on publicly available information

Hiroshi Kiyama

Department of Functional Anatomy and Neuroscience, Nagoya University Graduate School of Medicine, Nagoya, Japan

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
KHKoichiro Haruwaka
Koichiro Haruwaka
AIAko Ikegami
Ako Ikegami
YTYoshihisa Tachibana
Yoshihisa Tachibana
NONobuhiko Ohno
Nobuhiko Ohno
HKHiroyuki Konishi
Hiroyuki Konishi
HWHiroaki Wake
Hiroaki Wake
Microglia survey brain parenchyma, responding to injury and infections. Microglia also respond to systemic disease, but the role of blood–brain barrier (BBB) integrity in this process remains unclear. Using simultaneous in vivo imaging, we demonstrated that systemic inflammation induces CCR5-dependent migration of brain resident microglia to the cerebral vasculature. Vessel-associated microglia initially maintain BBB integrity via expression of the tight-junction protein Claudin-5 and make physical contact with endothelial cells. During sustained inflammation, microglia phagocytose astrocytic end-feet and impair BBB function. Our results show microglia play a dual role in maintaining BBB integrity with implications for elucidating how systemic immune-activation impacts neural functions.

1 August 2004 in Molecular and Cellular Biology
Verified
Journal Article
Open access
PDF file
MMMirei Murakami
Mirei Murakami
TITomoko Ichisaka
Tomoko Ichisaka
MMMitsuyo Maeda
Mitsuyo Maeda
NONoriko Oshiro
Noriko Oshiro
KHKenta Hara
Kenta Hara
SYShinya Yamanaka
Shinya Yamanaka
TOR is a serine-threonine kinase that was originally identified as a target of rapamycin in Saccharomyces cerevisiae and then found to be highly conserved among eukaryotes. In Drosophila melanogaster, inactivation of TOR or its substrate, S6 kinase, results in reduced cell size and embryonic lethality, indicating a critical role for the TOR pathway in cell growth control. However, the in vivo functions of mammalian TOR (mTOR) remain unclear. In this study, we disrupted the kinase domain of mouse mTOR by homologous recombination. While heterozygous mutant mice were normal and fertile, homozygous mutant embryos died shortly after implantation due to impaired cell proliferation in both embryonic and extraembryonic compartments. Homozygous blastocysts looked normal, but their inner cell mass and trophoblast failed to proliferate in vitro. Deletion of the C-terminal six amino acids of mTOR, which are essential for kinase activity, resulted in reduced cell size and proliferation arrest in embryonic stem cells. These data show that mTOR controls both cell size and proliferation in early mouse embryos and embryonic stem cells.

1 July 2003 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
HOHitoshi Osaka
Hitoshi Osaka
YWYu-Lai Wang
Yu-Lai Wang
KTKoji Takada
Koji Takada
STShuichi Takizawa
Shuichi Takizawa
RSRieko Setsuie
Rieko Setsuie
KWKeiji Wada
Keiji Wada
Mammalian neuronal cells abundantly express a deubiquitylating enzyme, ubiquitin carboxy-terminal hydrolase 1 (UCH L1). Mutations in UCH L1 are linked to Parkinson's disease as well as gracile axonal dystrophy ( gad ) in mice. In contrast to the UCH L3 isozyme that is universally expressed in all tissues, UCH L1 is expressed exclusively in neurons and testis/ovary. We found that UCH L1 associates and colocalizes with monoubiquitin and elongates ubiquitin half-life. The gad mouse, in which the function of UCH L1 is lost, exhibited a reduced level of monoubiquitin in neurons. In contrast, overexpression of UCH L1 caused an increase in the level of ubiquitin in both cultured cells and mice. These data suggest that UCH L1, with avidity and affinity for ubiquitin, insures ubiquitin stability within neurons. This study is the first to show the function of UCH L1 in vivo .

6 August 2018 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
PDF file
HKHiroyuki Konishi
Hiroyuki Konishi
HKHiroshi Kiyama
Hiroshi Kiyama
Microglia are activated after neuronal injury and in neurodegenerative diseases, and trigger neuroinflammation in the central nervous system (CNS). Microglia-derived neuroinflammation has both beneficial and detrimental effects on neurons. Because the timing and magnitude of microglial activation is thought to be a critical determinant of neuronal fate, understanding the molecular mechanisms underlying microglial activation is required to enable establishment of microglia-targeted therapies for neural diseases. Plasma membrane receptors play primary roles as activators of microglia and in this review, we focus on a receptor complex involving triggering receptor expressed on myeloid cells 2 (TREM2) and DNAX-activating protein of 12 kDa (DAP12), both of which are causative genes for Nasu-Hakola disease, a dementia with bone cysts. Recent transcriptome approaches demonstrated TREM2/DAP12 signaling as the principal regulator that transforms microglia from a homeostatic to a neural disease-associated state. Furthermore, animal model studies revealed critical roles for TREM2/DAP12 in the regulation of microglial activity, including survival, phagocytosis, and cytokine production, not only in Alzheimer's disease but also in other neural diseases, such as Parkinson's disease, demyelinating disease, ischemia, and peripheral nerve injury. Intriguingly, while TREM2/DAP12-mediated microglial activation is detrimental for some diseases, including peripheral nerve injury, it is beneficial for other diseases. As the role of activated microglia differs among disease models, TREM2/DAP12 signaling may result in different outcomes in different diseases. In this review we discuss recent perspectives on the role of TREM2/DAP12 in microglia and their contribution to neural diseases.

1 March 1985 in Brain Research
Verified
Journal Article
Closed access
YLY. Lee
Y. Lee
YKY. Kawai
Y. Kawai
SSS. Shiosaka
S. Shiosaka
KTK. Takami
K. Takami
HKH. Kiyama
H. Kiyama
MTM. Tohyama
M. Tohyama

1 June 2001 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
KSKeiro Shirotani
Keiro Shirotani
STSatoshi Tsubuki
Satoshi Tsubuki
NINobuhisa Iwata
Nobuhisa Iwata
YTYoshie Takaki
Yoshie Takaki
WHWakako Harigaya
Wakako Harigaya
TSTakaomi C. Saido
Takaomi C. Saido
To identify the amyloid β peptide (Aβ) 1–42-degrading enzyme whose activity is inhibited by thiorphan and phosphoramidon in vivo, we searched for neprilysin (NEP) homologues and cloned neprilysin-likepeptidase (NEPLP) α, NEPLP β, and NEPLP γ cDNAs. We expressed NEP, phosphate-regulating gene with homologies to endopeptidases on the X chromosome (PEX), NEPLPs, and damage-induced neuronal endopeptidase (DINE) in 293 cells as 95- to 125-kDa proteins and found that the enzymatic activities of PEX, NEPLP α, and NEPLP β, as well as those of NEP and DINE, were sensitive to thiorphan and phosphoramidon. Among the peptidases tested, NEP degraded both synthetic and cell-secreted Aβ1–40 and Aβ1–42 most rapidly and efficiently. PEX degraded cold Aβ1–40 and NEPLP α degraded both cold Aβ1–40 and Aβ1–42, although the rates and the extents of the digestion were slower and less efficient than those exhibited by NEP. These data suggest that, among the endopeptidases whose activities are sensitive to thiorphan and phosphoramidon, NEP is the most potent Aβ-degrading enzyme in vivo. Therefore, manipulating the activity of NEP would be a useful approach in regulating Aβ levels in the brain.